Engineering Clostridium acetobutylicum for Enhanced Solvent Production by Overexpression of Pyruvate Decarboxylase from Zymomonas mobilis

被引:2
|
作者
Dharani, S. R. [1 ]
Fathima, A. A. [1 ]
Sarath, R. [1 ]
Ramya, M. [1 ]
机构
[1] SRM Inst Sci & Technol, Mol Genet Lab, Dept Genet Engn, Chennai 603203, Tamil Nadu, India
关键词
biofuels; acetone-butanol-ethanol fermentation; Clostridium acetobutylicum; metabolic engineering; pyruvate decarboxylase; CONTINUOUS CULTURES; ETHANOL-PRODUCTION; ESCHERICHIA-COLI; EXPRESSION; GENES; SOLVENTOGENESIS; ACID; NADH; FERMENTATIONS; METABOLISM;
D O I
10.1134/S0003683821050045
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Clostridium acetobutylicum DSM 792 has been characterized as a native acetone-butanol-ethanol (ABE) fermenting bacterium. C. acetobutylicm is used as a model organism to improve solvent production by metabolic engineering strategies. In this study, the ABE pathway in C. acetobutylicum was modified by overexpressing the pyruvate decarboxylase gene from Zymomonas mobilis under the control of 2 promoters, namely Pferr and Ppta (promoters of genes encoding pyruvate ferredoxin oxidoreductase and phosphotransacetylase) and the recombinant strains were designated as DSM 792(pPDC1) and DSM 792(pPDC2). The specific activity of the alcohol dehydrogenases in the pdc-expressing strains was higher than that in the wild-type strain. In batch fermentation experiments, the total ABE production from the recombinant strains DSM 792 (pPDC1) and DSM 792 (pPDC2) was 1.57 and 7.9 g/L, respectively, which was higher when compared to the wild type ABE production (0.64 g/L) under uncontrolled pH. The alcohol to acetone ratio (BE/A) was found to be 2.28, 2.77, and 5.26 in wild type, DSM 792 (pPDC1), and DSM 792 (pPDC2), respectively. This suggests that the re-routing of pyruvate by overexpression of the pdc could play a role in the generation of more reducing equivalents towards ethanol and butanol production.
引用
收藏
页码:611 / 617
页数:7
相关论文
共 50 条
  • [31] Metabolic engineering of Clostridium acetobutylicum for enhanced production of butyric acid
    Jang, Yu-Sin
    Woo, Hee Moon
    Im, Jung Ae
    Kim, In Ho
    Lee, Sang Yup
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2013, 97 (21) : 9355 - 9363
  • [32] Metabolic engineering of Clostridium acetobutylicum for enhanced production of butyric acid
    Yu-Sin Jang
    Hee Moon Woo
    Jung Ae Im
    In Ho Kim
    Sang Yup Lee
    Applied Microbiology and Biotechnology, 2013, 97 : 9355 - 9363
  • [34] Enhanced butanol production in Clostridium acetobutylicum ATCC 824 by double overexpression of 6-phosphofructokinase and pyruvate kinase genes
    Ventura, Jey-R S.
    Hu, Hui
    Jahng, Deokjin
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2013, 97 (16) : 7505 - 7516
  • [35] Enhanced butanol production in Clostridium acetobutylicum ATCC 824 by double overexpression of 6-phosphofructokinase and pyruvate kinase genes
    Jey-R S. Ventura
    Hui Hu
    Deokjin Jahng
    Applied Microbiology and Biotechnology, 2013, 97 : 7505 - 7516
  • [36] Enhanced production of butanol and acetoin by heterologous expression of an acetolactate decarboxylase in Clostridium acetobutylicum
    Shen, Xiaoning
    Liu, Dong
    Liu, Jun
    Wang, Yanyan
    Xu, Jiahui
    Yang, Zhengjiao
    Guo, Ting
    Niu, Huanqing
    Ying, Hanjie
    BIORESOURCE TECHNOLOGY, 2016, 216 : 601 - 606
  • [37] Regulation of solvent production in Clostridium acetobutylicum
    Girbal, L
    Soucaille, P
    TRENDS IN BIOTECHNOLOGY, 1998, 16 (01) : 11 - 16
  • [39] Continuous production of (R)-phenylacetylcarbinol in an enzyme-membrane reactor using a potent mutant of pyruvate decarboxylase from Zymomonas mobilis
    Goetz, G
    Iwan, P
    Hauer, B
    Breuer, M
    Pohl, M
    BIOTECHNOLOGY AND BIOENGINEERING, 2001, 74 (04) : 317 - 325
  • [40] Construction of Zymomonas mobilis mutant with a decreased pyruvate decarboxylase activity and its biotechnological application
    Strazdina, I.
    Balodite, E.
    Galinina, N.
    Lasa, Z.
    Rutkis, R.
    Kalnenieks, U.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 124 : 20 - 20